Pharma Catalysts
Scope
Catalyst

Tue, Jun 9, 2026

1 updates
PRTC
2:00 AM

PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

RNS Number: 5025H PureTech Health PLC 09 June 2026 9 June 2026 PureTech Health plc PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers PureTech Health plc (LSE: PRTC) (" PureTech "

Trial Results • Phase 1Results event Mon, Jun 8, 2026puretechhealth.com

Wed, Apr 22, 2026

1 updates
PRTC
7:00 AM

PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory (R/R) High-Risk (HR) Myelodysplastic Syndrome (MDS) and R/R Acute Myeloid Leukemia (AML)

RNS Number: 4332B PureTech Health PLC 22 April 2026 22 April 2026 PureTech Health plc PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory (R/R) High-Risk (HR) Myelodysplastic Syndrome (MDS) and R/R Acute Myeloid Leukemia (AML) Phase 1b dataset with

Trial Results • Phase 1puretechhealth.com

Thu, Apr 2, 2026

2 updates
PRTC
12:00 AM

PureTech Founded Entity Seaport Therapeutics Announces Positive Proof of Concept Topline Results from Ongoing Phase 1 Trial of GlyphAgo™ in Healthy Volunteers

PureTech Health plc PureTech Founded Entity Seaport Therapeutics Announces Positive Proof of Concept Topline Results from Ongoing Phase 1 Trial of GlyphAgo TM in Healthy Volunteers PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company

Trial Results • Phase 1puretechhealth.com